Computer-Simulated Mechanism of Fatty Acid Synthase Inhibitor TVB-2640 in Hepatocellular Carcinoma

Jiaxu Cui

doi:10.54097/gq22gw78

Authors

Jiaxu Cui

DOI:

https://doi.org/10.54097/gq22gw78

Keywords:

TVB-2640, FASN, HCC, Molecular Docking

Abstract

Hepatocellular carcinoma (HCC), a highly lethal primary liver cancer, ranks among the most prevalent malignancies worldwide. Fatty acid synthase (FASN) is overexpressed in multiple cancers. This study analyzed the correlation between FASN expression and survival rates in HCC patients using clinical data and Kaplan-Meier survival curves, revealing that elevated FASN levels are associated with poor prognostic outcomes. Through molecular docking, we demonstrated that the FASN inhibitor TVB-2640 targets the KS domain of FASN. Further mechanistic analysis suggests that TVB-2640 inhibits HCC progression by suppressing FASN activity, positioning it as a potential therapeutic candidate for HCC.

Downloads

Download data is not yet available.

References

[1] Bicer, F. et al. (2023) ‘Advances in immunotherapy for hepatocellular carcinoma (HCC)’, Current Oncology, 30(11), pp. 9789–9812. doi:10.3390/curroncol30110711.

[2] Zeng H, Chen W, Zheng R, et al. Changing cancer survival in China during 2003⁃15: a pooled analysis of 17 population-based cancer registries [J]. The Lancet Global health, 2018, 6(5): e555⁃e567.

[3] Huang, J. et al. (2024) ‘FASN inhibition decreases MHC-I degradation and synergizes with PD-L1 checkpoint blockade in hepatocellular carcinoma’, Cancer Research, 84(6), pp. 855–871. doi: 10.1158/0008-5472.can-23-0966.

[4] Kim, D.W., Talati, C. and Kim, R. (2017) ‘Hepatocellular carcinoma (HCC): Beyond sorafenib—chemotherapy’, Journal of Gastrointestinal Oncology, 8(2), pp. 256–265. doi:10. 21037/ jgo.2016.09.07.

[5] Serzan, M.T. and Atkins, M.B. (2021) ‘Current and emerging therapies for first line treatment of metastatic clear cell renal cell carcinoma’, Journal of Cancer Metastasis and Treatment [Preprint]. doi:10.20517/2394-4722.2021.76.

[6] Fhu, C.W. and Ali, A. (2020) ‘Fatty acid synthase: An emerging target in cancer’, Molecules, 25(17), p. 3935. doi:10.3390/molecules25173935.

[7] Wei, W. et al. (2023) ‘FBXW7β loss-of-function enhances FASN-mediated lipogenesis and promotes colorectal cancer growth’, Signal Transduction and Targeted Therapy, 8(1). doi:10.1038/s41392-023-01405-8.

[8] Falchook, G. et al. (2021) ‘First-in-human study of the safety, pharmacokinetics, and pharmacodynamics of first-in-class fatty acid synthase inhibitor TVB-2640 alone and with a taxane in advanced tumors’, EClinicalMedicine, 34, p. 100797. doi:10. 1016/ j.eclinm.2021.100797.

[9] Kelly, W. et al. (2024) Phase II Investigation of TVB-2640 (Denifanstat) with Bevacizumab in Patients with First Relapse High-Grade Astrocytoma [Preprint]. doi:10.1158/1078-0432. c. 6637741.

[10] FASN inhibition targets multiple drivers of NASH by reducing steatosis, inflammation and fibrosis in preclinical models.

[11] TVB-2640 (FASN Inhibitor) for the Treatment of Nonalcoholic Steatohepatitis: FASCINATE-1, a Randomized, Placebo- Controlled Phase 2a Trial.

[12] Tian, L.-Y., Smit, D.J. and Jücker, M. (2023) ‘The role of PI3K/AKT/mTOR signaling in hepatocellular carcinoma metabolism’, International Journal of Molecular Sciences, 24(3), p. 2652. doi:10.3390/ijms24032652.

[13] Bottegoni, G. (2011) ‘Protein-ligand docking’, Frontiers in Bioscience, 16(1), p. 2289. doi:10.2741/3854.

[14] Zheng, L. et al. (2022) ‘Improving protein–ligand docking and screening accuracies by incorporating a scoring function correction term’, Briefings in Bioinformatics, 23(3). doi:10.1093/bib/bbac051.

[15] Eberhardt, J. et al. (2021) ‘AutoDock Vina 1.2.0: New Docking Methods, expanded force field, and python bindings’, Journal of Chemical Information and Modeling, 61(8), pp. 3891–3898. doi: 10.1021/acs.jcim.1c00203.

[16] Sung H, Ferlay J,Siegel RL,et al.Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries.CA Cancer J Clin, 2021, 71 (3): 209-249.

[17] Jones, S.F. and Infante, J.R. (2015) ‘Molecular pathways: Fatty acid synthase’, Clinical Cancer Research, 21(24), pp. 5434–5438. doi: 10.1158/1078-0432.ccr-15-0126.